6:33 PM
 | 
Dec 17, 2012
 |  BC Extra  |  Company News

NICE now recommends Revolade for ITP

The U.K.'s NICE issued draft guidance recommending the use of idiopathic thrombocytopenic purpura (ITP) drug Revolade eltrombopag from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), reversing the agency's 2010 final guidance. The recommendation...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >